A Delaware federal judge on June 24 granted summary judgment to Axinn client Alvogen in a lawsuit brought by Novartis AG over a generic version of the Exelon dementia treatment patch.  After the close of fact discovery, Novartis granted a covenant not to sue to Alvogen.  Axinn partner Chad Landmon and associate Thomas Hedemann represented Alvogen.  

Click here to read about the judgment in Law360’s article.